Fig. 2From: A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in ChinaForest plot for subgroup analyses of ORR in the mITT population. cGVHD chronic graft-versus-host disease, CI confidence interval, mITT modified intent-to-treat, ORR overall response rate, QD once dailyBack to article page